文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

伴有和不伴有脉络膜新生血管的慢性中心性浆液性脉络膜视网膜病变半量光动力疗法的两年疗效。

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.

机构信息

Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Department of Ophthalmology, Kobe City Eye Hospital, Kobe, Hyogo, Japan.

出版信息

PLoS One. 2023 May 2;18(5):e0284979. doi: 10.1371/journal.pone.0284979. eCollection 2023.


DOI:10.1371/journal.pone.0284979
PMID:37130134
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10153719/
Abstract

PURPOSE: To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV). METHODS: In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT. RESULTS: A significant intergroup difference was noted in terms of age (P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P < 0.01). CONCLUSIONS: A htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods.

摘要

目的:比较半量光动力疗法(htPDT)治疗慢性中心性浆液性脉络膜视网膜病变(cCSC)合并和不合并脉络膜新生血管(CNV)的两年疗效。

方法:在这项回顾性研究中,我们纳入了 88 例 88 只眼的 cCSC 患者,这些患者均接受了 htPDT 治疗,随访时间超过 24 个月。在 htPDT 治疗前,患者被分为合并 CNV(21 只眼)和不合并 CNV(67 只眼)两组。在 PDT 治疗前和治疗后 1、3、6、12 和 24 个月,评估最佳矫正视力(BCVA)、中心视网膜厚度(CRT)、中心凹下脉络膜厚度(SCT)和视网膜下液(SRF)的存在情况。

结果:在年龄方面,两组间存在显著的组间差异(P = 0.038)。在不合并 CNV 的眼中,BCVA 和 SCT 在所有时间点均有显著改善,但在合并 CNV 的眼中仅在 24 个月时有改善。两组 CRT 在所有时间点均显著降低。在所有时间点,两组间 BCVA、SCT 和 CRT 均无显著组间差异。两组间复发性和持续性 SRF 的发生率存在显著差异(无 CNV 组为 22.4%(22/99),有 CNV 组为 52.4%(11/21),P = 0.013;无 CNV 组为 26.9%(26/97),有 CNV 组为 57.1%(12/21),P = 0.017)。CNV 的存在与初始 PDT 后 SRF 的复发和持续性显著相关(P = 0.007 和 0.028)。Logistic 回归分析显示,初始 PDT 后 24 个月时的 BCVA 与基线 BCVA 显著相关(P < 0.01),而不是 CNV 的存在。

结论:对于 cCSC 患者,与不合并 CNV 的患者相比,CNV 的存在与 htPDT 后 SRF 的复发和持续性降低有关。在 24 个月的随访期间,CNV 眼可能需要额外的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d445/10153719/0bb91810e838/pone.0284979.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d445/10153719/0bb91810e838/pone.0284979.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d445/10153719/0bb91810e838/pone.0284979.g001.jpg

相似文献

[1]
Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.

PLoS One. 2023

[2]
RETROSPECTIVE ANALYSIS OF THE PRESENCE OF CHOROIDAL NEOVASCULARISATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY WITH THE AID OF PHOTODYNAMIC THERAPY.

Cesk Slov Oftalmol. 2021

[3]
Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.

Photodiagnosis Photodyn Ther. 2020-9

[4]
Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report.

BMC Ophthalmol. 2019-3-8

[5]
Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Eur J Ophthalmol. 2020-9

[6]
Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.

Graefes Arch Clin Exp Ophthalmol. 2018-8

[7]
3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.

Sci Rep. 2021-6-24

[8]
Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.

Photodiagnosis Photodyn Ther. 2021-3

[9]
Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.

Am J Ophthalmol. 2015-7

[10]
Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.

Eur J Ophthalmol. 2021-11

引用本文的文献

[1]
Predictive Factors for Morphological and Functional Improvements in Long-Lasting Central Serous Chorioretinopathy Treated with Photodynamic Therapy.

Biomedicines. 2025-4-11

本文引用的文献

[1]
Risk factors and characteristics of central serous chorioretinopathy with later development of macular neovascularisation detected on OCT angiography: a retrospective multicentre observational study.

BMJ Open Ophthalmol. 2022-4

[2]
Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2022-7

[3]
3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.

Sci Rep. 2021-6-24

[4]
Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity.

Pharmaceuticals (Basel). 2021-3-28

[5]
Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.

PLoS One. 2021

[6]
CHOROIDAL NEOVASCULARIZATION SECONDARY TO PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY: Incidence, Risk Factors, and Clinical Outcomes.

Retina. 2021-8-1

[7]
Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity.

PLoS One. 2020-10-12

[8]
Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.

Photodiagnosis Photodyn Ther. 2020-9

[9]
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.

Br J Ophthalmol. 2020-11

[10]
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).

Graefes Arch Clin Exp Ophthalmol. 2019-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索